NCT02810392View on ClinicalTrials.gov

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 4, 2020

Study Completion Date

March 4, 2020

Conditions
Stroke
Interventions
DRUG

Intranasal Insulin

Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.

DRUG

Intranasal saline

Delivery is with the Vianase device, 0.5 cc of normal saline

Trial Locations (1)

27157-1043

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT02810392 - Intranasal Insulin and Post-stroke Cognition: A Pilot Study | Biotech Hunter | Biotech Hunter